Our controlled human malaria infection study led by Dr. Sara Healy using the 'Chemoprophylaxis Vaccination' or CVac approach was just accepted to Clinical Infectious Diseases. This study followed up on an earlier NEJM paper that showed potent protection when Plasmodium-infected mosquito bites were given during chloroquine prophylaxis. In our newly-accepted study, the chloroquine CVac approach was not as protective as reported in the NEJM study. Our study also showed that addition of primaquine to chloroquine prophylaxis enhanced CVac-mediated protection, if primaquine was given at the right time. CVac has also been attempted with aseptically-manufactured sporozoites administered intradermally but showed better protection following intravenous administration of that product. Check out the new CID paper at: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz1010/5588862
|
Lab PostUpdates about lab activities, papers and other insights! Archives
April 2024
Categories |